Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBP NASDAQ:CRBU NASDAQ:DARE NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$11.29+2.2%$9.64$6.72▼$20.56$199.40M2.68218,373 shs73,508 shsCRBUCaribou Biosciences$1.99-1.8%$1.96$0.77▼$3.54$197.86M2.271.28 million shs590,464 shsDAREDare Bioscience$2.60+3.0%$1.91$1.27▼$9.19$37.77M1.09379,013 shs259,418 shsTLSATiziana Life Sciences$1.50-2.0%$1.31$1.14▼$2.60$190.89M0.42188,882 shs29,050 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals+0.73%+7.18%+12.65%+39.39%+71.16%CRBUCaribou Biosciences+4.64%+8.56%+5.18%+29.30%+162.17%DAREDare Bioscience-8.36%+7.69%+37.70%+49.11%-13.40%TLSATiziana Life Sciences-3.16%+14.18%+29.66%+8.51%-0.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$11.29+2.2%$9.64$6.72▼$20.56$199.40M2.68218,373 shs73,508 shsCRBUCaribou Biosciences$1.99-1.8%$1.96$0.77▼$3.54$197.86M2.271.28 million shs590,464 shsDAREDare Bioscience$2.60+3.0%$1.91$1.27▼$9.19$37.77M1.09379,013 shs259,418 shsTLSATiziana Life Sciences$1.50-2.0%$1.31$1.14▼$2.60$190.89M0.42188,882 shs29,050 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals+0.73%+7.18%+12.65%+39.39%+71.16%CRBUCaribou Biosciences+4.64%+8.56%+5.18%+29.30%+162.17%DAREDare Bioscience-8.36%+7.69%+37.70%+49.11%-13.40%TLSATiziana Life Sciences-3.16%+14.18%+29.66%+8.51%-0.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 2.82Moderate Buy$43.88288.76% UpsideCRBUCaribou Biosciences 2.75Moderate Buy$8.67334.86% UpsideDAREDare Bioscience 2.33Hold$10.00285.36% UpsideTLSATiziana Life Sciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest DARE, CRBU, CRBP, and TLSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026CRBUCaribou Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.005/6/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/29/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/20/2026CRBPCorbus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CRBUCaribou Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DAREDare Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026CRBUCaribou Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/25/2026CRBUCaribou Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/10/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $57.002/18/2026CRBPCorbus Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$8.40 per shareN/ACRBUCaribou Biosciences$11.16M17.71N/AN/A$1.31 per share1.52DAREDare Bioscience$1.03M36.68N/AN/A$0.20 per share12.98TLSATiziana Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$78.54M-$5.98N/AN/AN/AN/A-65.76%-57.88%5/12/2026 (Estimated)CRBUCaribou Biosciences-$148.12M-$1.42N/AN/AN/A-1,189.14%-84.17%-60.51%5/14/2026 (Estimated)DAREDare Bioscience-$13.40M-$1.25N/AN/AN/AN/AN/A-56.52%5/14/2026 (Estimated)TLSATiziana Life Sciences-$18.43MN/AN/AN/AN/AN/AN/AN/A6/18/2026 (Estimated)Latest DARE, CRBU, CRBP, and TLSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026DAREDare Bioscience-$0.33N/AN/AN/A$0.03 millionN/A5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26-$1.23+$0.03-$1.23N/AN/A5/7/2026Q1 2026CRBUCaribou Biosciences-$0.33-$0.26+$0.07-$0.26$2.21 million$2.40 million5/1/2026Q4 2025TLSATiziana Life SciencesN/A-$0.2750N/A-$0.2750N/AN/A3/26/2026Q4 2025DAREDare Bioscience-$0.44-$0.02+$0.42-$0.02$0.75 million$1.02 million3/9/2026Q4 2025CRBPCorbus Pharmaceuticals-$1.78-$1.25+$0.53-$1.25$1.11 millionN/A3/5/2026Q4 2025CRBUCaribou Biosciences-$0.33-$0.28+$0.05-$0.28$1.96 million$3.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A8.078.07CRBUCaribou BiosciencesN/A6.226.22DAREDare BioscienceN/A1.141.14TLSATiziana Life SciencesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%CRBUCaribou Biosciences77.51%DAREDare Bioscience6.70%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals3.50%CRBUCaribou Biosciences8.54%DAREDare Bioscience4.10%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4017.74 million17.12 millionOptionableCRBUCaribou Biosciences10099.18 million90.71 millionOptionableDAREDare Bioscience3014.56 million13.96 millionNot OptionableTLSATiziana Life Sciences8127.26 million76.58 millionOptionableDARE, CRBU, CRBP, and TLSA HeadlinesRecent News About These CompaniesTiziana Life Sciences Delays Annual 20-F FilingMay 2, 2026 | theglobeandmail.comWall Street Zen Downgrades Tiziana Life Sciences (NASDAQ:TLSA) to SellApril 18, 2026 | marketbeat.comTiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and ...April 17, 2026 | finanznachrichten.deTiziana says intranasal drug shows potential to ease Long COVID “brain fog”April 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive FunctionApril 16, 2026 | globenewswire.comTiziana Life Sciences to present Phase 2a MSA study at World Parkinson CongressApril 14, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson CongressApril 14, 2026 | globenewswire.comTiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with AgingApril 1, 2026 | uk.finance.yahoo.comTiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain agingApril 1, 2026 | proactiveinvestors.comTiziana reports biomarker gains for nasal MS therapy in progressive diseaseFebruary 25, 2026 | proactiveinvestors.comTiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRAFebruary 25, 2026 | globenewswire.comWhile insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownershipFebruary 9, 2026 | finance.yahoo.comTiziana Life Sciences publishes positive study on intranasal MS therapyJanuary 20, 2026 | proactiveinvestors.comTiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal ForalumabJanuary 20, 2026 | globenewswire.comTiziana Life Sciences announces closing of oversubscribed $8.8M offeringJanuary 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary SharesJanuary 16, 2026 | globenewswire.comTiziana Life Sciences unveils registered direct offering of up to $17.6MJanuary 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 MillionJanuary 16, 2026 | globenewswire.comTiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San FranciscoJanuary 9, 2026 | globenewswire.comTiziana Life Sciences submits annual safety report for intranasal foralumab to FDADecember 29, 2025 | proactiveinvestors.comTiziana Files Annual Safety Report for Intranasal Foralumab with FDADecember 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDARE, CRBU, CRBP, and TLSA Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$11.29 +0.25 (+2.23%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Caribou Biosciences NASDAQ:CRBU$1.99 -0.04 (-1.82%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Dare Bioscience NASDAQ:DARE$2.60 +0.08 (+2.98%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Tiziana Life Sciences NASDAQ:TLSA$1.50 -0.03 (-1.96%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
